首页 | 官方网站   微博 | 高级检索  
     

益气复脉注射液治疗心力衰竭的系统评价
引用本文:连宝涛,李泽彰,陈嘉城,蔡源媛,叶晓庆.益气复脉注射液治疗心力衰竭的系统评价[J].中国实验方剂学杂志,2016,22(8):215-220.
作者姓名:连宝涛  李泽彰  陈嘉城  蔡源媛  叶晓庆
作者单位:广州中医药大学, 广州 510405,广州中医药大学, 广州 510405,广州中医药大学, 广州 510405,广州中医药大学, 广州 510405,广州中医药大学, 广州 510405
基金项目:国家自然科学基金青年项目(61301294);国家级大学生创新创业训练项目(201510572007)
摘    要:目的:系统评价益气复脉注射液联合西药常规治疗心力衰竭的临床疗效。方法:计算机检索Pub Med,CENTRAL,EMbase,VIP,CNKI,CBM和Wanfang等数据库,纳入随机对照试验(RCTs),经过文献筛选和评价质量后提取有效数据进行Meta分析。结果:共纳入13个RCTs合计1 001例患者。Meta分析结果显示,益气复脉注射液联合西药常规治疗心力衰竭在提高临床综合疗效OR=3.09,95%CI(2.05,4.67),P0.000 01],左室射血分数MD=4.84,95%CI(3.56,6.13),P0.000 01],心输出量MD=0.30,95%CI(0.19,0.42),P0.000 01],6 min步行距离MD=39.03,95%CI(25.06,53.00),P0.000 01],降低NT-pro BNPMD=-67.72,95%CI(-110.30,-25.13),P=0.002],缩短左心室收缩末期内径MD=-2.94,95%CI(-4,86,-1.02),P=0.000 3]等指标上均优于单用西药组,其差异均具有统计学意义,但两组在缩短左心室舒张末期内径MD=-2.06,95%CI(-4.70,0.58),P=0.13]和提高舒张早期二尖瓣血流峰值/舒张晚期二尖瓣血流峰值MD=0.06,95%CI(-0.03,0.15),P=0.21]的差异无统计学意义。结论:益气复脉注射液联合西药常规治疗心力衰竭的临床疗效优于单用西药。

关 键 词:益气复脉注射液  心力衰竭  随机对照试验  系统评价
收稿时间:8/6/2015 12:00:00 AM

Systematic Review of Yiqi Fumai Injection for Patients with Heart Failure
LIAN Bao-tao,LI Ze-zhang,CHEN Jia-cheng,CAI Yuan-yuan and YE Xiao-qing.Systematic Review of Yiqi Fumai Injection for Patients with Heart Failure[J].China Journal of Experimental Traditional Medical Formulae,2016,22(8):215-220.
Authors:LIAN Bao-tao  LI Ze-zhang  CHEN Jia-cheng  CAI Yuan-yuan and YE Xiao-qing
Affiliation:Guangzhou University of Chinese Medicine, Guangzhou 510405, China,Guangzhou University of Chinese Medicine, Guangzhou 510405, China,Guangzhou University of Chinese Medicine, Guangzhou 510405, China,Guangzhou University of Chinese Medicine, Guangzhou 510405, China and Guangzhou University of Chinese Medicine, Guangzhou 510405, China
Abstract:Objective: To systematically review the effectiveness of Yiqi Fumai injection combined with western medicine for heart failure. Method: Databases such as PubMed, CENTRAL, EMbase, VIP, CNKI, CBM and Wanfang were electronically searched to collect the randomized controlled trials (RCTs). After document screening and quality evaluation, Meta-analysis was conducted for valid data. Result: Thirteen RCTs involving 1001 patients were included. The results of meta-analysis showed that the combination of Yiqi Fumai injection and western medicine was superior to the western medicine alone in improving clinical comprehensive efficacyOR=3.09, 95%CI (2.05, 4.67), P<0.00001], left ventricular ejection fractionMD=4.84, 95%CI (3.56, 6.13), P<0.00001], cardiac outputMD=0.30, 95%CI (0.19, 0.42), P<0.00001], 6 minutes walking distanceMD=39.03, 95%CI (25.06, 53.00), P<0.00001], reducing NT-proBNPMD=-67.72, 95%CI (-110.30, -25.13), P=0.002], and shortening left ventricular end systolic dimension (LVESD)MD=-2.94, 95%CI (-4.86, -1.02), P=0.0003], with statistically significant differences between two groups. But there was no significant difference between two groups in shortening left ventricular end diastolic dimension (LVEDD)MD=-2.06, 95%CI (-4.70, 0.58), P=0.13]and improving E/AMD=0.06, 95%CI (-0.03, 0.15), P=0.21]. Conclusion: Combination of Yiqi Fumai injection and western medicine has higher clinical efficacy than western medicine alone for the treatment of heart failure.
Keywords:Yiqi Fumai injection  heart failure  randomized controlled trial  systematic review
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号